TFB Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$753K Sell
819
-169
-17% -$171K 0.39% 58
2025
Q4
$1.06M Sell
988
-10
-1% -$9.56K 0.3% 78
2025
Q3
$811K Sell
998
-673
-40% -$501K 0.24% 106
2025
Q2
$1.3M Sell
1,671
-86
-5% -$66.8K 0.34% 70
2025
Q1
$1.45M Buy
1,757
+52
+3% +$43.3K 0.42% 55
2024
Q4
$1.32M Sell
1,705
-272
-14% -$225K 0.38% 58
2024
Q3
$1.75M Buy
1,977
+46
+2% +$41.4K 0.52% 41
2024
Q2
$1.75M Buy
1,931
+187
+11% +$150K 0.57% 39
2024
Q1
$1.35M Buy
1,744
+844
+94% +$601K 0.49% 49
2023
Q4
$525K Buy
+900
New +$525K 0.27% 85
2023
Q3
Sell
-914
Closed -$429K 175
2023
Q2
$429K Buy
914
+110
+14% +$46.1K 0.19% 129
2023
Q1
$276K Buy
804
+44
+6% +$14.8K 0.21% 102
2022
Q4
$278K Buy
+760
New +$269K 0.23% 92

Other funds holding LLY

TFB Advisors's LLY Position: Q1 2026 in Review

TFB Advisors reduced its Eli Lilly (LLY) stake by 17% in Q1 2026, selling an estimated $171K and leaving 819 shares worth $753K. The position accounts for 0.39% of the portfolio, ranked #58.

TFB Advisors first reported a position in LLY in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.75M in Q3 2024. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • TFB Advisors held 819 shares of Eli Lilly worth $753K as of Q1 2026.
  • TFB Advisors sold 169 Eli Lilly shares in Q1 2026, an estimated $171K.
  • Eli Lilly made up 0.39% of TFB Advisors's portfolio in Q1 2026, its #58 holding.
  • TFB Advisors first reported a position in Eli Lilly in Q4 2022 and has held it in 13 quarters since.
  • TFB Advisors's Eli Lilly position peaked at $1.75M in Q3 2024.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on TFB Advisors's 13F filing for Q1 2026, filed 20 Apr 2026.